noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

NAI - Natural Alternatives[...]

Statement of Changes in Beneficial Ownership (Form 4)
United States Attorney's Office[...]

Maryland Woman Sentenced For Laundering Funds Stolen From Fraud Schemes
Berkeley College

Save the Date: Berkeley College Hosts Media Literacy Panel with NPR[...]

Healthcare

Cytokinetics Incorporated

02/17/2026 | Press release | Distributed by Public on 02/17/2026 06:31

Material Event (Form 8-K)

Item 8.01 Other Events.

Cytokinetics, Incorporated today announced that the European Commission has approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy in adult patients. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity.

Cytokinetics Incorporated published this content on February 17, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on February 17, 2026 at 12:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]